Exelixis, Inc. - Common Stock (NQ:EXEL)

58.90 +0.51 (+0.87%)

Delayed Quote Updated: 1:16 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

23 24 Next >

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

February 14, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

The 3 Best Biotech Stocks to Buy in February 2024 ↗

February 13, 2024

The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.

Via InvestorPlace

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

February 13, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

Recap: Exelixis Q4 Earnings ↗

February 06, 2024

Via Benzinga

Earnings Scheduled For February 6, 2024 ↗

February 06, 2024

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.

Via Benzinga

Earnings Preview For Exelixis ↗

February 05, 2024

Via Benzinga

Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies

February 14, 2024

From FN Media Group LLC

Via GlobeNewswire

In the world of growth stocks, NASDAQ:EXEL shines as a value proposition. ↗

February 05, 2024

NASDAQ:EXEL, a growth stock which is not overvalued.

Via Chartmill

Breaking Down Exelixis: 7 Analysts Share Their Views ↗

January 30, 2024

Via Benzinga

NASDAQ:EXEL is showing good growth, while it is not too expensive. ↗

December 21, 2023

Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

February 10, 2024

The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.

Via The Motley Fool

Topics Stocks

3 Attractive Medical Stocks To Buy After Earnings ↗

February 08, 2024

Quite a few top-rated stocks have highlighted this week’s earnings lineup with now appearing to be an ideal time to buy. Following their favorable quarterly results, here are 3 intriguing healthcare...

Via Talk Markets

Exelixis (EXEL) Q4 2023 Earnings Call Transcript ↗

February 06, 2024

EXEL earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

February 06, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

February 01, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

January 25, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024

January 23, 2024

From Exelixis, Inc.

Via Business Wire

Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study ↗

January 23, 2024

Bristol Myers Squibb & Exelixis Inc revealed four-year follow-up results from CheckMate -9ER trial.

Via Benzinga

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

January 22, 2024

From Bristol Myers Squibb

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

January 22, 2024

Via Benzinga

3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024 ↗

January 21, 2024

These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024.

Via InvestorPlace

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

January 18, 2024

From Exelixis, Inc.

Via Business Wire

3 Pharma Stocks Could Be the Pills Your Portfolio Needs ↗

January 18, 2024

These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.

Via InvestorPlace

Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review ↗

January 12, 2024

The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.

Via Investor's Business Daily

Topics ETFs

Jim Cramer Likes This 'Well-Run' Airline, Says This Entertainment Stock Has 'Balance Sheet From Hell' ↗

January 12, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Franco-Nevada Corporation (NYSE: FNV) is a "great diversified

Via Benzinga

Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation. ↗

January 11, 2024

Investors should take note ofEXELIXIS INC (NASDAQ:EXEL), a growth stock that remains attractively priced.

Via Chartmill

Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today? ↗

January 08, 2024

Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an

Via Benzinga

Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes ↗

January 08, 2024

Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.

Via Investor's Business Daily

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

January 07, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024

January 02, 2024

From Exelixis, Inc.

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.